EMEA-001849-PIP02-15-M02

Key facts

Invented name
Bavencio
Active substance
avelumab
Therapeutic area
Oncology
Decision number
P/0242/2018
PIP number
EMEA-001849-PIP02-15-M02
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)
Route(s) of administration
Intravenous use
Contact for public enquiries
Merck KGaA

Tel. +49 6151 725200
E-mail: service@merckgroup.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating